Ivermectin and Cancer: Current Research, Evidence & Clinical Trials

🧬 Introduction

Ivermectin is an established antiparasitic medicine, but researchers have also investigated whether it may have anticancer activity. Laboratory and animal studies have reported effects on cancer-cell proliferation, programmed cell death and several molecular signaling pathways. However, these findings remain predominantly preclinical and do not establish ivermectin as an effective cancer treatment in humans.

Interest in the subject continues to generate research, including clinical investigation of ivermectin in combination with cancer immunotherapy. This article reviews what researchers currently know, what remains uncertain, and where clinical research is heading.

---

⚙️ How Is Ivermectin Being Studied in Cancer Research?

Researchers suggest that Ivermectin may interfere with various molecular and cellular pathways involved in tumor growth:

• Inhibition of the PAK1 Pathway: Preclinical studies have investigated whether ivermectin can influence PAK1-related signaling pathways involved in cancer-cell growth. These findings remain experimental and have not established a clinical anticancer effect in humans.
• Induction of Apoptosis: Ivermectin may promote programmed cell death in cancer cells, effectively reducing tumor size in preclinical models.
• Immune Modulation: The drug might enhance the body’s immune response, enabling T-cells to detect and destroy cancer cells more efficiently.
• Suppression of WNT-TCF Signaling: Overactivation of this pathway is linked to many cancer types. Ivermectin’s suppression of WNT signaling could inhibit tumor growth.
• Anti-angiogenesis: By reducing the formation of new blood vessels, it may starve tumors of nutrients and oxygen, limiting their spread.

---

🔬 Key Research Studies & Findings

Here are notable studies exploring Ivermectin’s anti-cancer potential:

Evidence level	What researchers have found
Cell studies	Anticancer effects have been reported in multiple cancer-cell models.
Animal studies	Some models have shown tumor-related effects, but animal findings cannot establish human effectiveness.
Early human research	Limited clinical investigation has taken place.
Large clinical trials	There is currently no large-scale randomized evidence establishing ivermectin as a cancer treatment.
Regulatory status	Ivermectin is not an established FDA-approved cancer therapy.

Key Areas of Ivermectin Cancer Research

1. Zhang et al. (2019, Biochemical Pharmacology):
   Found that Ivermectin suppressed colorectal cancer cell growth by disrupting cell cycle regulation.
2. Li et al. (2020, Frontiers in Pharmacology):
   Demonstrated that Ivermectin induced cell death in lung and breast cancer cell lines.
3. Gao et al. (2021):
   Found Ivermectin targets the mTOR signaling pathway, limiting cancer cell viability.
4. NIH PubMed Database:
   Over 100+ publications mention Ivermectin’s emerging oncological applications.

Current Clinical Trial: Ivermectin With Immunotherapy

Interest in ivermectin has progressed beyond laboratory research into early clinical investigation. A registered Phase 2 study, ICONIC (NCT07487805), is investigating ivermectin in combination with immune-checkpoint inhibition in adults with solid tumors.

The study is designed to evaluate safety and pharmacodynamic effects, including changes in immune markers. It is not designed to establish ivermectin as a proven cancer treatment, and results are not yet available.

---

🛑 Is Ivermectin Approved for Cancer Treatment?

No. Ivermectin is not an established FDA-approved cancer treatment. Its approved human uses relate to specific parasitic conditions and vary by formulation and jurisdiction. Research into possible anticancer applications remains investigational.

Current clinical research is therefore focused on determining whether ivermectin has meaningful biological or therapeutic effects in cancer patients rather than assuming that laboratory findings translate into clinical benefit.

---

🌍 Where Is Ivermectin Being Considered in Oncology?

Despite the lack of formal approval, interest in ivermectin for cancer is increasing in several parts of the world:

• India & Latin America – Some integrative oncology clinics are including ivermectin in off-label protocols, often alongside natural supplements.
• Eastern Europe – Advocacy groups are calling for more trials and compassionate use access.
• Africa & Southeast Asia – A few NGOs are exploring its use due to affordability and accessibility.

⚠️ These uses are not standard and should be approached with caution.

---

📦 Ivermectin Pharmaceutical Sourcing for Research and Institutional Requirements?

Globalstar Company supports pharmaceutical sourcing and contract manufacturing through established manufacturing partners in India. Depending on the project requirements and applicable regulations, documentation, formulation development, private-label manufacturing and export support may be available for qualified institutional and pharmaceutical buyers.

Research institutions and organizations involved in clinical development should ensure that all investigational-product requirements, regulatory approvals and applicable import permissions are addressed before sourcing.

• Third-party labeling
• Dossier documentation
• COA, COPP, and stability reports
• Clinical trial formulation batches

Visit our Iverstar page.

Important: Research Is Not the Same as Treatment

Ivermectin’s potential anticancer activity is an area of scientific investigation. Findings from laboratory experiments or animal models do not establish that ivermectin can treat or cure cancer in humans. Patients should not replace or delay evidence-based cancer treatment because of claims about ivermectin.